Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
Adamina M, Warlaumont M, Berger M, Däster S, Delaloye R, Digklia A, Gloor B, Fritsch R, Koeberle D, Koessler T, Lehmann K, Müller P, Peterli R, Ris F, Steffen T, Weisshaupt C, Hübner M. Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. Cancers (Basel) 2022; 14
01.09.2022Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin.
01.09.2022Cancers (Basel) 2022; 14
Adamina Michel, Warlaumont Maxime, Berger Martin D, Däster Silvio, Delaloye Raphaël, Digklia Antonia, Gloor Beat, Fritsch Ralph, Koeberle Dieter, Koessler Thibaud, Lehmann Kuno, Müller Phaedra, Peterli Ralph, Ris Frédéric, Steffen Thomas, Weisshaupt Christian, Hübner Martin
Patient satisfaction with divided anesthesia care.
Koster K, Björklund C, Fenner S, Flierler W, Laupheimer M, Burri K, Nübling M, Heidegger T. Patient satisfaction with divided anesthesia care. Anaesthesiologie 2022
29.08.2022Patient satisfaction with divided anesthesia care.
29.08.2022Anaesthesiologie 2022
Koster Kira-Lee, Björklund Carolin, Fenner Sebastian, Flierler Wolfgang Johann, Laupheimer Michael, Burri Katharina, Nübling Matthias, Heidegger Thomas
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung Cancer 2022; 172:154-159.
28.08.2022Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
28.08.2022Lung Cancer 2022; 172:154-159
Addeo Alfredo, Rothschild Sacha I, Holer Lisa, Schneider Martina, Waibel Christine, Haefliger Simon, Mark Michael, Fernandez Eugenio, Mach Nicolas, Mauti Laetitia, Jermann Philip, Alborelli Ilaria, Calgua Byron, Savic-Prince Spasenija, Joerger Markus, Früh Martin
Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
Koster K, Appenzeller C, Lauber A, Früh M, Schmid S. Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Case Rep Oncol 2022; 15:720-725.
26.08.2022Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
26.08.2022Case Rep Oncol 2022; 15:720-725
Koster Kira-Lee, Appenzeller Christina, Lauber Arno, Früh Martin, Schmid Sabine
Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
Su E, Fischer K, R Demmer-Steingruber, Nigg S, Güsewell S, Albrich W, Rothermundt C, Silzle T, Kahlert C. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment. ESMO Open 2022; 7:100587.
24.08.2022Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.
24.08.2022ESMO Open 2022; 7:100587
Su E, Fischer Katharina S, R Demmer-Steingruber, Nigg Susanne, Güsewell Sabine, Albrich Werner, Rothermundt Christian, Silzle Tobias, Kahlert Christian
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J, Furlanetto J, Zahm D, Hanusch C, GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022
09.08.2022Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
09.08.2022Ann Oncol 2022
Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P A, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober Jens, Braun M, Rey J, Blohmer J-U, Furlanetto J, Zahm D-M, Hanusch C, GBG and AGO-B
A High-Energy Density Li-Ion Hybrid Capacitor Fabricated from Bio-Waste Derived Carbon Nanosheets Cathode and Graphite Anode.
Nanaji K, Pappu S, Anandan S, Rao T. A High-Energy Density Li-Ion Hybrid Capacitor Fabricated from Bio-Waste Derived Carbon Nanosheets Cathode and Graphite Anode. Glob Chall 2022; 6:2200082.
09.08.2022A High-Energy Density Li-Ion Hybrid Capacitor Fabricated from Bio-Waste Derived Carbon Nanosheets Cathode and Graphite Anode.
09.08.2022Glob Chall 2022; 6:2200082
Nanaji Katchala, Pappu Samhita, Anandan Srinivasan, Rao Tata Nageswara
Forgiveness and Reconciliation
Renz M. Forgiveness and Reconciliation - Initiating Individuation and Enabling Liberation. Routledge, Taylor & Francis Ltd, 2022. ISBN 9781032316970.
26.07.2022Forgiveness and Reconciliation
26.07.2022Routledge, Taylor & Francis Ltd, ISBN 9781032316970
Renz Monika
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol 2022; 88:5336-5347.
23.07.2022Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
23.07.2022Br J Clin Pharmacol 2022; 88:5336-5347
Schmulenson Eduard, Bovet Cédric, Theurillat Regula, Decosterd Laurent Arthur, Largiadèr Carlo R, Prost Jean-Christophe, Csajka Chantal, Bärtschi Daniela, Guckenberger Matthias, von Moos Roger, Bastian Sara, Jörger Markus, Jaehde Ulrich
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen J, Löwenberg B, Manz M, Biemond B, Westerweel P, Klein S, Fehr M, Sinnige H, Efthymiou A, Legdeur M, Pabst T, Gregor M, van der Poel M, Deeren D, Tick L, Jongen-Lavrencic M, van Obbergh F, Boersma R, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele G. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia 2022; 36:2189-2195.
22.07.2022Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
22.07.2022Leukemia 2022; 36:2189-2195
Janssen J J W M, Löwenberg Bob, Manz M, Biemond B J, Westerweel P E, Klein S K, Fehr M, Sinnige H A M, Efthymiou Anna, Legdeur M C J C, Pabst T, Gregor M, van der Poel M W M, Deeren Dries, Tick L W, Jongen-Lavrencic Mojca, van Obbergh F, Boersma R S, de Weerdt Okke, Chalandon Yves, Heim D, Spertini Olivier, van Sluis G, Graux Carlos, Stüssi G, van Norden Y, Ossenkoppele G J
Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice.
Rovó A, Baierlein-Leimbach C, Medri C, Chanias I, Errass L, Fehr T, Triemer T, McCarthy-Pontier D, Lehmann T. Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice. J Clin Med 2022; 11
21.07.2022Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice.
21.07.2022J Clin Med 2022; 11
Rovó Alicia, Baierlein-Leimbach Claudia, Medri Cesare, Chanias Ioannis, Errass Loreen, Fehr Theresa, Triemer Therese, McCarthy-Pontier Daphne B, Lehmann Thomas
Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson I, Lin Y, Lam C, Shao H, Tharp K, Hale M, Kasap C, Mariano M, Kishishita A, Patiño Escobar B, Mandal K, Steri V, Wang D, Phojanakong P, Tuomivaara S, Hann B, Driessen C, Van Ness B, Gestwicki J, Wiita A. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Cell Chem Biol 2022; 29:1288-1302.e7.
18.07.2022Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
18.07.2022Cell Chem Biol 2022; 29:1288-1302.e7
Ferguson Ian D, Lin Yu-Hsiu T, Lam Christine, Shao Hao, Tharp Kevin M, Hale Martina, Kasap Corynn, Mariano Margarette C, Kishishita Audrey, Patiño Escobar Bonell, Mandal Kamal, Steri Veronica, Wang Donghui, Phojanakong Paul, Tuomivaara Sami T, Hann Byron, Driessen Christoph, Van Ness Brian, Gestwicki Jason E, Wiita Arun P
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson I, Patiño-Escobar B, Tuomivaara S, Lin Y, Nix M, Leung K, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong S, Wolf J, Martin T, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey A, Mullins R, Eyquem J, Wells J, Wiita A. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun 2022; 13:4121.
15.07.2022The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
15.07.2022Nat Commun 2022; 13:4121
Ferguson Ian D, Patiño-Escobar Bonell, Tuomivaara Sami T, Lin Yu-Hsiu T, Nix Matthew A, Leung Kevin K, Kasap Corynn, Ramos Emilio, Nieves Vasquez Wilson, Talbot Alexis, Hale Martina, Naik Akul, Kishishita Audrey, Choudhry Priya, Lopez-Girona Antonia, Miao Weili, Wong Sandy W, Wolf Jeffrey L, Martin Thomas G, Shah Nina, Vandenberg Scott, Prakash Sonam, Besse Lenka, Driessen Christoph, Posey Avery D, Mullins R Dyche, Eyquem Justin, Wells James A, Wiita Arun P
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle D, Hess D, Moccia A, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Adv 2022; 6:3911-3920.
12.07.2022SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
12.07.2022Blood Adv 2022; 6:3911-3920
Stathis Anastasios, Mey Ulrich, Schär Sämi, Hitz Felicitas, Pott Christiane, Mach Nicolas, Krasniqi Fatime, Novak Urban, Schmidt Christian, Hohloch Karin, Kienle Dirk, Hess Dagmar, Moccia Alden A, Unterhalt Michael, Eckhardt Katrin, Hayoz Stefanie, Forestieri Gabriela, Rossi Davide, Dirnhofer Stefan, Ceriani Luca, Sartori Giulio, Bertoni Francesco, Buske Christian, Zucca Emanuele, Hiddemann Wolfgang
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer
Hamilton E, Chen Y, Zhang W, Huober J, Hegg R, Jerusalem G, Manikhas A, Petrakova K, Chen S, Ozyilkan O, Cortes J, Martín M. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer. Breast Cancer Res Treat 2022; 195:55-64.
12.07.2022nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer
12.07.2022Breast Cancer Res Treat 2022; 195:55-64
Hamilton Erika, Chen Yanyun, Zhang Wei, Huober Jens, Hegg Roberto, Jerusalem Guy, Manikhas Aleksey, Petrakova Katarina, Chen Shin-Cheh, Ozyilkan Ozgur, Cortes Javier, Martín Miguel
Correlation of age and the diameter of the cervical nerve roots C5 and C6 during the first 2 years of life analyzed by high-resolution ultrasound imaging.
van der Linde J, Jenny C, Hundsberger T, Broser P. Correlation of age and the diameter of the cervical nerve roots C5 and C6 during the first 2 years of life analyzed by high-resolution ultrasound imaging. Brain Behav 2022; 12:e2649.
10.07.2022Correlation of age and the diameter of the cervical nerve roots C5 and C6 during the first 2 years of life analyzed by high-resolution ultrasound imaging.
10.07.2022Brain Behav 2022; 12:e2649
van der Linde Jacoba, Jenny Carole, Hundsberger Thomas, Broser Philip
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
Ligorio F, Huober J, Moscetti L, Janni W, Coccia-Portugal M, Corsetto P, Belfiore A, Lorenzini D, Daidone M, Vingiani A, Gianni L, Pupa S, Bianchini G, Pruneri G, Nuciforo P, de Azambuja E, Izquierdo M, Di Cosimo S, Verderio P, Ciniselli C, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Vernieri C. Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. J Natl Cancer Inst 2022
05.07.2022Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab
05.07.2022J Natl Cancer Inst 2022
Ligorio Francesca, Huober Jens, Moscetti Luca, Janni Wolfgang, Coccia-Portugal Maria Antonia, Corsetto Paola Antonia, Belfiore Antonino, Lorenzini Daniele, Daidone Maria Grazia, Vingiani Andrea, Gianni Luca, Pupa Serenella Maria, Bianchini Giampaolo, Pruneri Giancarlo, Nuciforo Paolo, de Azambuja Evandro, Izquierdo Miguel, Di Cosimo Serena, Verderio Paolo, Ciniselli Chiara Maura, Pizzamiglio Sara, Castagnoli Lorenzo, Dugo Matteo, Galbardi Barbara, Salgado Roberto, Loi Sherene, Michiels Stefan, Triulzi Tiziana, Tagliabue Elda, El-Abed Sarra, Vernieri Claudio
Wunsch nach assistiertem Suizid? Von der Aufgabe, auf der Seite des Lebens zu stehen
Nestor K. Wunsch nach assistiertem Suizid? Von der Aufgabe, auf der Seite des Lebens zu stehen. Imago Hominis 2022; 29:10-89-99.
04.07.2022Wunsch nach assistiertem Suizid? Von der Aufgabe, auf der Seite des Lebens zu stehen
04.07.2022Imago Hominis 2022; 29:10-89-99
Nestor Karen
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V, Walter B, Fend F, Overkamp M, Rothermundt C, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS). BMC cancer 2022; 22:725.
02.07.2022Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
02.07.2022BMC cancer 2022; 22:725
Tsintari Vasileia, Walter Bianca, Fend Falko, Overkamp Mathis, Rothermundt Christian, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
Symptom Burden in Glioblastoma: A Prospective Pilot Study from Diagnosis to First Progression.
Roelcke U, Schwyzer L, Zeitlberger A, Hundsberger T. Symptom Burden in Glioblastoma: A Prospective Pilot Study from Diagnosis to First Progression. Oncology 2022; 101:145-152.
01.07.2022Symptom Burden in Glioblastoma: A Prospective Pilot Study from Diagnosis to First Progression.
01.07.2022Oncology 2022; 101:145-152
Roelcke Ulrich, Schwyzer Lucia, Zeitlberger Anna Maria, Hundsberger Thomas